166 related articles for article (PubMed ID: 35330827)
21. Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use Program.
Peters S; Curioni-Fontecedro A; Nechushtan H; Shih JY; Liao WY; Gautschi O; Spataro V; Unk M; Yang JC; Lorence RM; Carrière P; Cseh A; Chang GC
J Thorac Oncol; 2018 Dec; 13(12):1897-1905. PubMed ID: 30096481
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and Resistance of Afatinib in Chinese Non-Small Cell Lung Cancer Patients With
Song Z; Lv D; Chen S; Huang J; Wang L; Xu S; Chen H; Wang G; Lin Q
Front Oncol; 2021; 11():657283. PubMed ID: 34026634
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and Safety of Pyrotinib in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Multicenter, Retrospective, Real-World Study.
Zhang X; Li Z; Han L; Lv Z; Teng Y; Cui X; Zhou C; Wu H; Fang W; Xu L; Zhao S; Song C; Zheng Y; Gao T; Li M
Onco Targets Ther; 2022; 15():1067-1078. PubMed ID: 36199295
[TBL] [Abstract][Full Text] [Related]
24. Treatment with pyrotinib-based therapy in lapatinib-resistant HER2-positive metastatic breast cancer: a multicenter real-world study.
Hua Y; Li W; Jin N; Cai D; Sun J; Sun C; Yang F; Wu X; Huang X; Wang B; Yin Y
Ther Adv Med Oncol; 2022; 14():17588359221085232. PubMed ID: 35356262
[TBL] [Abstract][Full Text] [Related]
25. Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study.
Lai WV; Lebas L; Barnes TA; Milia J; Ni A; Gautschi O; Peters S; Ferrara R; Plodkowski AJ; Kavanagh J; Sabari JK; Clarke SJ; Pavlakis N; Drilon A; Rudin CM; Arcila ME; Leighl NB; Shepherd FA; Kris MG; Mazières J; Li BT
Eur J Cancer; 2019 Mar; 109():28-35. PubMed ID: 30685684
[TBL] [Abstract][Full Text] [Related]
26. Genomic landscape and efficacy of HER2-targeted therapy in patients with
Han Y; Xiong Y; Lu T; Chen R; Liu Y; Tang H; Geng R; Wang Y
Front Oncol; 2023; 13():1121708. PubMed ID: 37077822
[TBL] [Abstract][Full Text] [Related]
27. Molecular correlation of response to pyrotinib in advanced NSCLC with HER2 mutation: biomarker analysis from two phase II trials.
Mao S; Yang S; Liu X; Li X; Wang Q; Zhang Y; Chen J; Wang Y; Gao G; Wu F; Jiang T; Zhang J; Yang Y; Lin X; Zhu X; Zhou C; Ren S
Exp Hematol Oncol; 2023 Jun; 12(1):53. PubMed ID: 37296463
[TBL] [Abstract][Full Text] [Related]
28. Combination of In Silico Analysis and In Vitro Assay to Investigate Drug Response to Human Epidermal Growth Factor Receptor 2 Mutations in Lung Cancer.
Yu X; Wang T; Lou Y; Li Y
Mol Inform; 2016 Jan; 35(1):25-35. PubMed ID: 27491651
[TBL] [Abstract][Full Text] [Related]
29. Pyrotinib in the treatment of advanced lung adenocarcinoma with HER2 exon 20 mutation: a case report and literature review.
Luo Y; Yao B; Huang P; Zhao Y; Chen J
Ann Palliat Med; 2021 Dec; 10(12):12906-12910. PubMed ID: 35016465
[TBL] [Abstract][Full Text] [Related]
30. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
[TBL] [Abstract][Full Text] [Related]
31. HER2 Exon 20 Insertion Mutations in Lung Adenocarcinoma: Case Series and Response to Pyrotinib.
Zhang X; Lv J; Wu Y; Qin N; Ma L; Li X; Nong J; Zhang H; Zhang Q; Yang X; Shi H; Wang J; Zhang S
Front Oncol; 2020; 10():1162. PubMed ID: 32850330
[TBL] [Abstract][Full Text] [Related]
32. A multicenter-retrospective study of non-small-cell lung carcinoma harboring uncommon epidermal growth factor receptor (EGFR) mutations: different subtypes of EGFR exon 19 deletion-insertions exhibit the clinical characteristics and prognosis of non-small cell lung carcinoma.
Chen Y; Xu J; Zhang L; Song Y; Wen W; Lu J; Zhao Z; Kong W; Liu W; Guo A; Santarpia M; Yamada T; Cai X; Yu Z
Transl Lung Cancer Res; 2022 Feb; 11(2):238-249. PubMed ID: 35280318
[TBL] [Abstract][Full Text] [Related]
33. Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers.
Eng J; Hsu M; Chaft JE; Kris MG; Arcila ME; Li BT
Lung Cancer; 2016 Sep; 99():53-6. PubMed ID: 27565914
[TBL] [Abstract][Full Text] [Related]
34. Clinical benefit from afatinib in an advanced squamous cell lung carcinoma patient harboring
Gao Y; Zheng A; Zhu X; Song J; Xue Q
Onco Targets Ther; 2018; 11():8705-8710. PubMed ID: 30584328
[TBL] [Abstract][Full Text] [Related]
35. Phase 1b trial of anti-HER2 antibody inetetamab and pan-HER inhibitor pyrotinib in HER2-positive advanced lung cancer.
Huang Y; Zhao Y; Huang Y; Yang Y; Zhang Y; Hong S; Zhao H; Zhao S; Zhou T; Chen G; Zhou H; Ma Y; Zhou N; Zhang L; Fang W
MedComm (2020); 2024 May; 5(5):e536. PubMed ID: 38685972
[TBL] [Abstract][Full Text] [Related]
36. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.
Mazières J; Barlesi F; Filleron T; Besse B; Monnet I; Beau-Faller M; Peters S; Dansin E; Früh M; Pless M; Rosell R; Wislez M; Fournel P; Westeel V; Cappuzzo F; Cortot A; Moro-Sibilot D; Milia J; Gautschi O
Ann Oncol; 2016 Feb; 27(2):281-6. PubMed ID: 26598547
[TBL] [Abstract][Full Text] [Related]
37. Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases.
Yang JC; Schuler M; Popat S; Miura S; Heeke S; Park K; Märten A; Kim ES
J Thorac Oncol; 2020 May; 15(5):803-815. PubMed ID: 31931137
[TBL] [Abstract][Full Text] [Related]
38. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study.
Bilgin B; Sendur MAN; Yucel S; Celik E; Ozyukseler DT; Ayhan M; Basoglu T; Ilhan A; Akdeniz N; Gulmez A; Dogan I; Aktas BY; Gurbuz M; Koca S; Paydas S; Tatli AM; Cinkir HY; Alan O; Erol C; Hizal M; Kut E; Menevse S; Sakalar T; Taskaynatan H; Deniz GI; Karaagac M; Avci O; Sen E; Karatas F; Akinci MB; Dede DS; Demir A; Demirkazık A; Oksuzoglu B; Kilickap S; Yumuk F; Yalcin B
J Cancer Res Clin Oncol; 2021 Jul; 147(7):2145-2152. PubMed ID: 33433657
[TBL] [Abstract][Full Text] [Related]
39. Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase Inhibitors.
Rossi S; Toschi L; Finocchiaro G; Di Noia V; Bonomi M; Cerchiaro E; Ceresoli GL; Beretta GD; D'Argento E; Santoro A
Clin Lung Cancer; 2019 Mar; 20(2):82-87. PubMed ID: 30473385
[TBL] [Abstract][Full Text] [Related]
40. Real-world efficacy and safety of pyrotinib in patients with HER2-positive metastatic breast cancer: A prospective real-world study.
Zhang Q; He P; Tian T; Yan X; Huang J; Zhang Z; Zheng H; Zhong X; Luo T
Front Pharmacol; 2023; 14():1100556. PubMed ID: 37025489
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
